No interactions between heparin and atacicept, an antagonist of B cell survival cytokines. by Kowalczyk-Quintas, C. et al.
Received: 9 November 2018 Revised: 29 May 2019 Accepted: 5 July 2019
DOI: 10.1111/bph.14811BJPR E S E A R CH PA P E RNo interactions between heparin and atacicept, an antagonist
of B cell survival cytokinesChristine Kowalczyk‐Quintas1 | Daniela Willen2 | Laure Willen1 | Michaela Golob2 |
Sonia Schuepbach‐Mallepell1 | Benjamin Peter1 | Mahya Eslami1 | Michele Vigolo1 |
Hervé Broly4 | Eileen Samy3 | Özkan Yalkinoglu2 | Pascal Schneider11Department of Biochemistry, University of
Lausanne, Epalinges, Switzerland
2Clinical Pharmacology, Quantitative
Pharmacology, Global Early Development,
Merck KGaA, Darmstadt, Germany
3EMD Serono Research & Development
Institute, Inc., Billerica, MA, USA
4Biotech Process Sciences, Merck KGaA,
Corsier‐sur‐Vevey, Switzerland
Correspondence
Pascal Schneider, Department of Biochemistry,




Merck KGaA; Swiss National Science Founda-
tion, Grant/Award Number: 310030A_176256- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the
the original work is properly cited.
© 2019 The Authors. British Journal of Pharmacol
Abbreviations: APRIL, a proliferation‐inducing ligand; BAFF
activator and calcium‐modulator and cyclophilin ligand (CAM
Özkan Yalkinoglu and Pascal Schneider should be considere
Br J Pharmacol. 2019;1–15.Background and Purpose: The TNF family ligands, B cell activating factor of the
TNF family (BAFF, also known as B lymphocyte stimulator, BLyS) and a prolifera-
tion‐inducing ligand (APRIL), share the transmembrane activator and calcium‐modula-
tor and cyclophilin ligand (CAML)‐interactor (TACI) as one of their common receptors.
Atacicept, a chimeric recombinant TACI/IgG1‐Fc fusion protein, inhibits both ligands.
TACI and APRIL also bind to proteoglycans and to heparin that is structurally related
to proteoglycans. It is unknown whether the portion of TACI contained in atacicept
can bind directly to proteoglycans, or indirectly via APRIL, and whether this could
interfere with the anti‐coagulant properties of heparin.
Experimental Approach: Binding of atacicept and APRIL to proteoglycan‐positive
cells was measured by FACS. Activities of heparin and atacicept were measured with
activated factor Xa inhibition and cell‐based assays. Effects of heparin on circulating
atacicept was monitored in mice.
Key Results: Atacicept did not bind to proteoglycan‐positive cells, but when com-
plexed to APRIL could do so indirectly via APRIL. Multimers of atacicept obtained
after exposure to cysteine or BAFF 60‐mer bound directly to proteoglycans. Atacicept
alone, or in complex with APRIL, or in a multimeric form did not interfere with heparin
activity in vitro. Conversely, heparin did not influence inhibition of BAFF and APRIL
by atacicept and did not change circulating levels of atacicept.
Conclusions and Implications: Lack of detectable interference of APRIL‐bound or
free atacicept on heparin activity makes it unlikely that atacicept at therapeutic doses
will interfere with the function of heparin in vivo.- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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What is already known
• Interactions of the receptor TACI and its ligand APRIL
with proteoglycans are inhibited by heparin.
• Atacicept contains a portion of TACI that may potentially
interfere with heparin, directly or indirectly.
What this study adds
• Neither atacicept alone, nor atacicept–APRIL complexes,
nor atacicept multimers interfere with heparin activity.
• Conversely, heparin does not interfere with atacicept
activity and circulating levels of atacicept in mice.
What is the clinical significance
• There is no reason to suspect drug interference between
atacicept and heparin or heparin‐like anticoagulants.
2 KOWALCZYK‐QUINTAS ET AL.BJP1 | INTRODUCTION
The B cell activating factor of the TNF family (BAFF, also known as B
lymphocyte stimulator, BLyS) and a proliferation‐inducing ligand
(APRIL) play important roles in the generation, maintenance, and func-
tion of peripheral B cells at various stages of maturation (reviewed in
(Mackay & Schneider, 2009). To exert these effects, BAFF binds three
different receptors, the BAFF receptor (BAFFR), the transmembrane
activator and calcium‐modulator and cyclophilin ligand (CAML)‐
interactor (TACI), and the B cell maturation antigen (BCMA), whereas
APRIL only binds to TACI and BCMA (reviewed in Mackay &
Schneider, 2009). Because of their importance in B cell survival, BAFF
alone (Furie et al., 2011; Navarra et al., 2011) or BAFF and APRIL
(Isenberg et al., 2014; Merrill et al., 2018) have been targeted in
patients with autoimmune diseases involving pathogenic auto‐reactive
B cells. The anti‐BAFF monoclonal antibody belimumab is approved by
the Food and Drug Administration for the treatment of systemic
lupus erythematosus (SLE; Furie et al., 2011; Navarra et al., 2011),
while the dual BAFF and APRIL inhibitor atacicept, consisting of
the extracellular portion of TACI fused to the Fc portion of human
IgG1 modified to reduce interactions with complement and antibody
receptors, is in clinical development for the same disease (Isenberg et
al., 2014; Merrill et al., 2018). When cleaved at furin consensus sites,
the trans‐membrane proteins APRIL and BAFF are released as solu-
ble cytokines (see Bossen & Schneider, 2006). APRIL is a basic,
positively charged protein that can bind to negatively charged pro-
teoglycans, in particular through an amino acid sequence located
after the furin cleavage site (Hendriks et al., 2005; Ingold et al.,
2005). This binding is believed to concentrate and cross‐link APRIL
on cells to facilitate encounter with TACI and BCMA and possibly
create and stabilize chemical gradients of APRIL (Huard et al.,
2008; Kimberley et al., 2009). In B cells, TACI and heparan sulfate
proteoglycans were both required for APRIL to induce IgA produc-
tion (Sakurai et al., 2007). TACI was further reported to interact with
proteoglycans, which under certain conditions was sufficient to acti-
vate TACI signalling (Bischof et al., 2006). In another study, TACI‐Fc
bound syndecan‐1‐positive multiple myeloma cells unless heparin
was present or heparan sulfate chains were hydrolyzed by treatment
with heparitinase (Moreaux et al., 2009). Interactions of APRIL and
TACI with proteoglycans could invariably be disrupted by heparin
in all studies where this has been tested.
In blood, the serine protease inhibitor anti‐thrombin limits activa-
tion of coagulation proteases such as factor X and thrombin. The activ-
ity of anti‐thrombin is strongly activated by heparin and its low MW
forms, which are highly negatively charged sulfated glycosaminogly-
cans widely used as anti‐coagulants. Low MW heparins directly bind
anti‐thrombin, inducing conformational changes that place the reactive
centre loop in an ideal position to inhibit activated factor X, while lon-
ger forms of heparin can additionally create a physical bridge between
anti‐thrombin and thrombin to reinforce inhibition (Johnson, Li,
Adams, & Huntington, 2006; Li, Johnson, Esmon, & Huntington,
2004). Heparin has long been described to release into the blood cir-
culation a “clearing factor” for lipids, identified as lipoprotein lipase(Korn, 1955). Lipoprotein lipase is a soluble enzyme that remains
bound to the surface of endothelial cells by electrostatic interactions
with heparan sulfate proteoglycans. It can be released from endothelial
cells with heparin (Shimada, Gill, Silbert, Douglas, & Fanburg, 1981).
TACI, APRIL, and anti‐thrombin all can bind to heparin. This raises
the question of whether atacicept, which contains a portion of extra-
cellular TACI, may sequester heparin directly or indirectly, via APRIL,
and interfere with its anti‐coagulant action. Here, we show that this
is unlikely to be the case.2 | METHODS
2.1 | Human samples
Human serum samples were from patients with SLE who were
enrolled in the randomized, double‐blind, APRIL‐SLE trial
(ClinicalTrials.gov Identifier NCT00624338). In addition to standard‐
of‐care therapy, patients received 150‐mg atacicept subcutaneously
twice a week for 4 weeks and then weekly for 48 weeks (Isenberg et
al., 2014). Other sera samples obtained at various time points after a
single subcutaneous administration of 150‐mg atacicept in healthy
subjects were from study EMR700461‐022. Trials were conducted
according to the Declaration of Helsinki, applicable local regulations,
and the International Council for Harmonization guideline for Good
Clinical Practice.2.2 | Mice, cells, and reagents
Animal studies are reported in compliance with the ARRIVE guidelines
(Kilkenny et al., 2010) and with the recommendations made by the
British Journal of Pharmacology. Mouse and human APRIL both bind
to proteoglycans in a heparin‐sensitive manner (Hendriks et al.,
2005; Ingold et al., 2005). In addition, human TACI binds to mouse
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relevant model to test interactions of atacicept with heparin, endoge-
nous APRIL, and PGs. Mice were handled according to Swiss Federal
Veterinary Office guidelines. Experiments with animals performed in
this study were approved by the local institutional animal care and
use committee and by the Office Vétérinaire Cantonal du Canton de
Vaud (authorization 1370.6 to PS). Female C57BL/6 WT mice were
purchased from Envigo (Horst, Netherlands). Four to five animals per
cage were housed in a specific pathogen‐free facility at 21°C,
50 ± 10% humidity, with a 14‐hr:10‐hr light/night cycle. Mice were
provided with water at pH 2.8 and Global Rodent XP18 food (Kliba
Nafag). Cages were enriched with tunnel kraft, dome, sizzle ball, and
beech log (Serlab).
HEK293 (ATCC Cat# CRL‐1573, RRID:CVCL‐0045) and HEK293T
(ATCC Cat# CRL‐3216, RRID: CVCL‐0063) cells were obtained from
late Jürg Tschopp (University of Lausanne). HEK293 and HEK293‐
hBAFF full‐544 cells (Schneider et al., 1999) were cultured in
DMEM:F12 (1:1 v/v) supplemented with 2% fetal calf serum. 293T
cells were cultured in DMEM containing 10% fetal calf serum. CHO‐
S cells were from Thermoscientific (Cat# A1155701, RRID: CVCL‐
7183). Jurkat BCMA:Fas‐2309 cl13 and Jurkat JOM2‐BAFFR:Fas‐
2308 cl21 cells have been reported previously and were cultured in
RPMI supplemented with 10% fetal calf serum (Bossen et al., 2008;
Nys et al., 2013). These cell lines were not authenticated as theirTABLE 1 Plasmids used in this study
Plasmid Designation Protein encoded
ps544 hBAFF hBAFF (1–285)
ps657 Flag‐mBAFF HA signal‐Flag‐GPGQVQLHVD‐mBA
ps882 hTACI (2–159)‐Fc HA signal‐LD‐hTACI (aa 2–159)‐VD‐
ps926 hTACI (2–118)‐Fc HA signal‐LD‐hTACI (aa 2–110)‐VD‐
ps927 hTACI (2–70)‐Fc HA signal‐LD‐hTACI (aa 2–70)‐VD‐h
ps930 hEDAR‐Fc hEDAR (aa 1–183)‐VD‐hIgG1 (aa 24
ps952 hTACI (67–118)‐Fc HA signal‐LE‐hTACI (aa 67–118)‐VD
ps1011 hBCMA (1–54)‐Fc Ig signal‐VQC‐hBCMA (aa 1–54)‐VD
ps1088 Flag‐ACRP‐hAPRIL HA signal‐Flag‐GPGQVQLQ‐hACRP
ps1155 Fc‐hAPRIL A88 HA signal‐LD‐ hIgG1 (aa 245–470)‐R
ps1377 pMSCV‐puro Modified pMSCV‐puro (Clonetech) w
ps3139 hTNFR2‐PS‐Fc hTNFR2 (aa 1–257)‐VDHHHHHHLD
ps2297 mBAFFR‐Fc HA signal‐LD‐mBAFFR (aa 2–70)‐VD
ps2308 hBAFFR:Fas HA signal‐LE‐hBAFFR (aa 2–71)‐EFG
ps2309 hBCMA:Fas Ig signal‐VQCEVKLVPRGS‐hBCMA
ps2565 His6‐hBAFF MRGSHHHHHH‐h BAFF (aa 134–2
ps2825 Fc‐hBAFF HA signal‐LD‐hIgG1 (aa 245–470)‐R
ps3426 hTACI (1–118)‐Fc Modified Ig signal hTACI (aa 1–118)
ps3449 hBCMA (1–51)‐Fc Modified Ig signal hBCMA (aa 1–51
ps3613 hTACI (67–110)‐Fc Modified Ig signal hTACI (aa 67–110
ps3825 hTACI (31–110)‐Fc Modified Ig signal hTACI (aa 31–110
Note. HA signal = MAIIYLIILLFTAVRG. Ig signal = MNFGFSLIFLVLV
METDTLLLWVLLWVPGVHG. PreScission = LEVLFQGP. Flag = DYKDDDDK.identity does not impact on results interpretation. hTACI‐Fc (contain-
ing amino acid residues 2–159, or 1–118, or 2–118, or 2–70, or 67–
118, 67–110, or 30–110 of hTACI), hBCMA‐Fc (containing amino acid
residues 1–51 or 1–54), mBAFFR‐Fc, EDAR‐Fc, TNFR2‐Fc, Fc‐BAFF,
and Fc‐APRIL were produced in CHO‐S cells cultured in OptiMEM
without serum supplementation (or chemically defined MS‐CHO‐
PM209 medium, a Merck Serono proprietary formulation supplied by
Merck Millipore, for TACI‐Fc 30–110, and for TACI‐Fc 2–70 that
was produced in both media) and purified on Protein A Sepharose
or, when indicated, on Protein G Sepharose, essentially as described
(Schneider, 2000). Flag‐ACRP‐hAPRIL (Flag‐APRIL; produced in
HEK293 cells) and Flag‐mBAFF (produced by transient transfection
in 293T cells) were purified on anti‐Flag agarose, as described
(Schneider, 2000). BAFF 60‐mer was produced as described (Bossen
et al., 2008; Vigolo et al., 2018). Plasmids used in this study are
described in Table 1. Atacicept (TACI (30–110)‐Fc) and anti‐hTACI
mouse monoclonal antibodies ATA1 (250.14.1.1.4.3), ATA2
(251.15.1.1.1.5), and ATA3 (251.10.1.4.2.1) were provided by Merck
(Darmstadt, Germany). TNFR2‐Fc (etanercept, registered trade name
Enbrel) was purchased from the Pharmacy of Lausanne University
Hospital (CHUV). Anti‐mouse BAFF monoclonal antibodies 5A8 (rat
IgG1) and Sandy2 (mouse IgG1) were as described (Kowalczyk‐
Quintas et al., 2016). 5A8 (Enzo Life Sciences Cat# ALX‐804‐158‐
C100, RRID:AB_2050785) and Sandy‐2 (Adipogen Cat# AG‐20B‐Vector
PCR3
FF (aa 127–309) PCR3
hIgG1 (aa 245–470) PCR3
hIgG1 (aa 245–470) PCR3
IgG1 (aa 245–470) PCR3
5–470) PCR3
‐hIgG1 (aa 245–470) PCR3
‐PreScission‐hIgG1 (aa 245–470) PCR3
30 (aa 16–108)‐MQ‐hAPRIL (aa 105–250) PCR3
S‐CamLinker‐GSLQ‐hAPRIL (aa 105–250) PCR3
ith HindIII‐Bg1II‐EcoRI‐NotI‐XhoI‐HpaI‐ApaI cloning sites ps1377
‐PreScision‐hIgG1 (aa 245–470) PCR3
‐hIgG1 (aa 245–470) PCR3
SVD‐hFas (aa 169–335) ps1377
(aa 2–54)‐VD‐hFas (aa 169–335) ps1377
45) pQE9
S‐CamLinker‐GSLQ‐hBAFF (aa 136–285) PCR3
hIgG1 (aa 245–470; L258E, A353S, P354S) PCR3
)‐VDHHHHHHLD‐PreScission‐hIgG1 (aa 245–470) PCR3
)‐VD‐PreScission‐hIgG1 (aa 245–470) PCR3
)‐VD‐hIgG1 (aa 245–470)
LKG. CamLinker = PQPQPKPQPKPEPEGS. Modified Ig signal =
4 KOWALCZYK‐QUINTAS ET AL.BJP0063PF, RRID:AB_2490279) are also commercially available. Biotinyl-
ated anti‐Flag M2 antibody (Sigma‐Aldrich Cat# F9291, Lot
#087K6004, RRID:AB_439689), fatty acid‐free bovine serum albumin,
Zwittergent, and poly‐lysine were from Sigma‐Aldrich. The EnzCheck
lipase substrate, a triglyceride analogue, was purchased from
ThermoFischer. Heparin (Liquemin 5,000 IU·ml−1) was from
DrossaPharm (Basel, Switzerland). Biophen heparin (LRT) and Biophen
heparin calibrator kits were from Hyphen (Neuville‐sur‐Oise, France).
AlphaLISA acceptor beads and streptavidin‐coupled AlphaLISA donor
beads were purchased from PerkinElmer.
2.2.1 | Biotinylation
Antibodies in 1 ml of 0.1‐M Na‐borate pH 8.8 were biotinylated with
100‐μg EZ‐Link‐Sulfo‐NHS‐LC‐biotin (Pierce) per milligram of anti-
body for 2 hr at room temperature. The reaction was stopped by the
addition of 10 μl of 1‐M NH4Cl, and buffer was then exchanged for
PBS in a 30‐kDa cut‐off centrifugal device (Millipore).
2.2.2 | ELISA
ELISA plates were coated with atacicept at 1 μg·ml−1 in PBS, blocked,
and incubated with the indicated concentrations of Flag‐APRIL. Bind-
ing of Flag‐APRIL was revealed with appropriate anti‐Flag secondary
reagents.
2.2.3 | SDS‐PAGE and western blot
The immuno‐related procedures used comply with the recommenda-
tions made by the British Journal of Pharmacology. SDS‐PAGE was
performed under reducing or non‐reducing conditions, as mentioned.
Coomassie blue staining was performed with a semidry iD Stain
System (Eurogentech). Western blots were performed on nitrocellulose
membranes according to standard procedures and reveal with
horseradish peroxidase‐coupled donkey anti‐human IgG (Jackson
ImmunoResearch Labs #709‐036‐149, RRID:AB_2340498; 1/5,000),
orwith anti‐TACI ATA1 antibody at 1μg·ml−1, followed byHRP‐coupled
goat anti‐mouse IgG (Jackson ImmunoResearch Labs Cat #115‐035‐
146, RRID:AB_2307392; 1/5,000). Blots were revealed with ECL.
2.2.4 | Preparation of atacicept multimers
Eighty microlitres of atacicept at 75 mg·ml−1 was mixed with 80 μl of
20‐mM Na‐phosphate pH 7, 10 mM EDTA, with or without 20 mM
of freshly prepared cysteine. The mixture was incubated for 48 hr at
37°C with agitation and then size‐fractionated by gel permeation
chromatography.
2.2.5 | Preparation of Fc fragment
Four hundred microlitres of TNFR2‐His6‐Fc at 5 mg·ml
−1 in PBS, with a
PreScission cleavage site between the His tag and Fc, was digested for
48 hr at 4°C with 40 U·ml−1 of GST‐PreScission protease (GEHealthcare). Fc was recovered by affinity purification on Protein A‐
Sepharose, followed by gel permeation chromatography on Superdex‐
200 column and concentration on a 30‐kDa cut‐off centrifugal device.2.2.6 | Gel permeation chromatography
Protein A or Protein G‐purified TACI‐Fc or BCMA‐Fc were loaded in a
volume of 400 μl on a Superdex‐200 Increase column (GE Healthcare)
eluted in 20‐mM HEPES pH 8.2, 130‐mM NaCl with online absor-
bance monitoring at 280 nm, and 1‐mL fraction collection. Fractions
of interest were quantified by measuring absorbance at 280 nm and
by using the theoretical extinction coefficient. If necessary, they were
first concentrated on 30‐kDa cut‐off centrifugal devices. For the prep-
aration of atacicept multimers, samples were loaded in a volume of
160 μl on a Superdex‐200 Increase column eluted in 0.1‐M ammonium
acetate pH 7.2.2.7 | FACS
HEK293 or 293T cells were stained for 20 min on ice with Flag‐APRIL
or Fc‐containing proteins at the indicated concentrations. Atacicept‐
containing sera were used at a dilution of 1/5, followed by five
washes, for which care was taken to carefully suspend cells after each
wash and to drain all of the wash liquid to bring levels of soluble serum
human IgGs below the level that could quench the secondary staining
reagent. Binding of Flag‐APRIL was revealed with 2 μg·ml−1 of bio-
tinylated anti‐Flag antibody followed by phycoerythrin‐coupled
streptavidin (1/500; eBiosciences, Cat #12‐4317‐87, Lot #E01657‐
1636), while binding of Fc‐containing proteins was revealed with
1 μg·ml−1 of phycoerythrin‐coupled goat anti‐human IgG (1/500;
SouthernBiotech Cat #2040‐09, Lot #01316‐Q487, RRID:
AB_2795648). When present, heparin at a final concentration of
8 IU·ml−1 was added together with recombinant proteins, unless stated
otherwise. Samples were analysed with an Accuri 6 flow cytometer
(BectonDickinson).2.2.8 | Cytotoxicity assay
Cytotoxicity assays using BAFFR:Fas or BCMA:Fas cells were per-
formed essentially as described (Schneider, Willen, & Smulski, 2014).
Briefly, tests were performed with 3 to 4 × 104 cells per well in flat‐
bottomed 96‐well plates in a final volume of 100 μl of RPMI 10% fetal
calf serum and in the presence of the indicated concentrations of ago-
nists (Fc‐BAFF or Fc‐APRIL), inhibitors (atacicept or atacicept in mouse
plasma at a final plasma dilution of 1/1,000), and heparin. The mea-
surement of atacicept activity in plasma was performed independently
either in the presence or in the absence of heparin at 8 IU·ml−1. After
an overnight incubation at 37°C, 5% CO2, cell viability was monitored
with a colorimetric (PMS/MTS) test. When active atacicept was mea-
sured in plasma of mice treated with heparin, a correction factor was
applied to account for blood dilution induced by the intravenous injec-
tion, assuming a blood volume of 80 ml·kg−1.
KOWALCZYK‐QUINTAS ET AL. 5BJP2.2.9 | Activated factor X inhibition assay
Ten microlitres of calibration plasma (0, 0.38, 0.74, 1.12, or
1.55 IU·ml−1 heparin), 10 μl of potential inhibitors (PBS, 90 μg·ml−1
poly‐lysine in PBS, 100 μg·ml−1 recombinant proteins in PBS, undiluted
human sera), 50 μl of chromogenic factor X substrate, and 50 μl of
bovine factor Xa solution were mixed in a 96‐well plate and incubated
for 1 min at 37°C. The reaction was terminated by the addition of
50 μl of 50‐mM Na‐citrate pH 2.7, and absorbance was read at
405 nm. When two proteins were mixed, each was at a concentration
of 100 μg·ml−1. To correct for intrinsic coloration of sera, background
absorbance determined from reactions in which Na‐citrate pH 2.7 was
added before bovine factor Xa was subtracted. For the determination
of heparin activity in mouse plasma, the same test was done, using
10 μl of calibration plasma without heparin mixed with 10 μl of plasma
diluted 1/25 in PBS.
2.2.10 | Atacicept and heparin administration in mice
Eight‐week‐old female mice were acclimated for a week upon arrival,
attributed randomly to experimental groups and housed so that mice
from a given time point were distributed in different cages. Power cal-
culation: group size of six animals per group was chosen to detect dif-
ferences of one third between conditions, assuming variation
coefficients of 20%. Mice weighing 17.4 g on average (range 16.2 to
18.5 g) received atacicept subcutaneously at 5 mg·kg−1 on Day 0 or
were left untreated. One, 3, 7, or 14 days after atacicept administra-
tion, blood (~200 μl) was collected from the facial vein, located just
beneath the skin immediately caudal to the facial vibrissae at the cor-
ner of the jaw, with 5‐mm Goldenrod animal lancets (Braintree Scien-
tific) under anaesthesia with isoflurane. Blood was collected in EDTA‐
containing tubes (to get 5‐mM EDTA final) for plasma preparation.
Within 30 min after blood withdrawal, mice received heparin 200 IU·ml
i.v. at 1 IU·g−1, were left for 10 min, and then killed by CO2 inhalation.
Plasma was prepared on EDTA from blood collected by cardiac punc-
ture (at about 20 min post administration of heparin). For cardiac
puncture, the animal is placed on the back, and a 0.5 × 16 mm 25G
5/8″ needle is inserted slightly left of and under the sternum, directly
towards the head the animal, at an angle of 20–30° from horizontal.
For the Day 14 time point, when atacicept plasma levels were antici-
pated to be closer to background, 10 mice were used instead of six.
This does not introduce heterogeneity in group size as statistical anal-
ysis was performed between conditions at a given time point, and not
between time points. Experiments were not performed blinded (all
mice received the same dose of atacicept on Day 0, then heparin after
different days, and plasma collection methods before and after heparin
administration were distinct), but statistical tests for in vivo experi-
ments were performed blinded by an independent person.
2.2.11 | Lipase assay
The assay was performed essentially as described (Basu, Manjur, & Jin,
2011). Briefly, 1 μl of plasma was incubated in black 96‐well plates for1 hr at 37°C in 100 μl of 150‐mM NaCl, 20‐mM Tris–HCl pH 8, 1.5%
fatty acid‐free BSA, 0.0125% Zwittergent, 0.1 U·ml−1 heparin, and
0.62‐μM EnzCheck lipase substrate. Fluorescence (excitation at
482 nm, read at 515 nm) was monitored every 2 min with a
SpectraMax i3 device (Molecular devices). Lipase activity was
expressed as fluorescence at 18 min – fluorescence at 8 min.
2.2.12 | AlphaLISA
One milligram of AlphaLISA acceptor beads (Perkin‐Elmer) was coupled
for 24 hr at 37°C to 100 μg of monoclonal antibody ATA3 in 400 μl of
27‐mM Na‐phosphate pH 8, 5‐mM NaBH3CN, and 0.03% Tween‐20.
The reaction was stopped with 100 μl of carboxymethoxylamine at
65 mg·ml−1 in 0.8‐M NaOH for 1 hr at 37°C. Beads were washed in
0.1‐M Tris–HCl pH 8 and then stored at 5 mg·ml−1 in PBS 0.05%
Proclin‐300. Assays were performed in white shallow 384‐well plates
by mixing 2 μl of sample (plasma diluted 1/100 in assay buffer) with
8 μl of 75 ng·ml−1 of biotinylated ATA2 and 0.2 μg of ATA3 acceptor
beads in assay buffer. After 1‐hr incubation at room temperature,
0.4 μg of streptavidin‐coupled donor beads in 10 μl of assay buffer
was added. Emission at 615 nm after excitation at 680 nm was
recorded 10 to 15 min later with an Enspire plate reader (Perkin‐Elmer).
For the acid‐dissociation procedure, assays were performed with 1.8‐μl
sample (plasma diluted 1/100 in assay buffer), 0.2 μl of 4.25% o‐phos-
phoric acid, 0.8 μl of 350‐mM Tris HCl pH 10, 7.2 μl of a mix of
83 ng·ml−1 of biotinylated ATA2, and 0.2 μg of ATA3 acceptor beads.
Samples were either incubated in acid for 20 min at room temperature,
then neutralized with the mix of biotinylated ATA2, ATA3 beads and
Tris, or incubated in pre‐neutralized acid mixed with biotinylated
ATA2 and ATA3 beads. Samples were then incubated for 1 hr at room
temperature and measured as described above. When atacicept was
measured in plasma of mice treated with heparin, a correction factor
was applied to account for blood dilution induced by the intravenous
injection, assuming a blood volume of 80 ml·kg−1.
2.2.13 | Data and statistical analyses
The data and statistical analysis comply with the recommendations of
the British Journal of Pharmacology on experimental design and analysis
in pharmacology (Curtis et al., 2018). Normal distribution of data was
confirmed with normality tests (D'Agostino Pearson normality test
for n ≥ 8; Shapiro–Wilk test for n = 5 to 7). Comparison of two groups
was performed with paired Student's t test. Comparison of multiple
groups was performed by one‐way ANOVA followed, if F achieved
P < .05 and Bartlett's test indicated no significant variance inhomoge-
neity, by Bonferroni's multiple comparison tests using GraphPad Prism,
RRID:SCR_002798). Differences were considered statistically signifi-
cant when P < .05.
2.2.14 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corre-
sponding entries in http://www.guidetopharmacology.org, the
FIGURE 1 Atacicept does not bind proteoglycans directly but can do so via APRIL. (a) ELISA assay to monitor the binding of Flag‐APRIL to coated
atacicept. The experiment was performed three times. (b–d) HEK293 cells and the same cells stably transfected with full‐length human BAFF
(HEK293‐BAFF) were stained with atacicept and/or Flag‐APRIL at the indicated concentrations, in the presence or absence of heparin (8 IU·ml−1).
Binding of Flag‐APRIL and atacicept were respectively revealed with anti‐Flag and anti‐Fc secondary reagents. Results shown are from one of
three similar experiments with similar results. (b) Selected histograms of the experiment described above in which the X‐axis displays fluorescence
intensity on a log scale (3 × 102 to 2 × 105). (c) Mean fluorescence intensity (MFI) of atacicept binding to HEK293‐BAFF cells, in the presence or
absence of heparin. (d) MFI of Flag‐APRIL or atacicept binding to HEK293 cells in the presence or absence. APRIL, a proliferation‐inducing ligand;
BAFF, B cell activating factor of the TNF family
6 KOWALCZYK‐QUINTAS ET AL.BJPcommon portal for data from the IUPHAR/BPS Guide to PHARMA-
COLOGY (Harding et al., 2018), and are permanently archived in the
Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017).3 | RESULTS
3.1 | Atacicept binds to proteoglycans indirectly via
APRIL
When coated to an ELISA plate, the TACI‐Fc fusion protein atacicept
bound a recombinant form of human Flag‐APRIL in a concentration‐
dependent manner (Figure 1a). This recombinant Flag‐APRIL started
at amino acid residue alanine 105 of APRIL, just after the furin cleav-
age site, and comprised the N‐terminal section of mature solubleAPRIL that contributes to interaction with proteoglycans (Hendriks
et al., 2005; Ingold et al., 2005). Flag‐APRIL stained HEK293 cells in
a concentration‐dependent manner, and its binding was abolished
by the addition of heparin (Figure 1b, top row). Flag‐APRIL binding
still occurred in the presence of increasing concentrations of
atacicept (Figure 1b, top part, and Figure 1d, top panel), indicating
that although atacicept can bind to APRIL (Figure 1a), atacicept does
not prevent the binding of APRIL to cell surface proteoglycans
(Figure 1b,d). Atacicept could bind HEK293 cells stably transfected
with full length BAFF, regardless of the presence or absence of hep-
arin (Figure 1b, last column, and Figure 1c), but atacicept alone had
no detectable interaction with untransfected HEK293 cells that
express cell surface proteoglycans (Figure 1b, column 4). In the pres-
ence of APRIL, atacicept binding to HEK293 cells could be monitored
by direct revelation of atacicept with anti‐Fc secondary reagents
KOWALCZYK‐QUINTAS ET AL. 7BJP(Figure 1b, bottom two rows, and Figure 1d, bottom panel). This
binding was inhibited in the presence of heparin (Figure 1b, column
5, and Figure 1d). Taken together, these data show that atacicept,
unlike Flag‐APRIL, does not bind directly to HEK293 cells but can
do so in the presence of Flag‐APRIL, in a heparin‐sensitive way. This
suggests that atacicept does not bind cell surface proteoglycans






FIGURE 2 Dimeric recombinant TACI‐Fc does not bind to proteogly
extracellular domain of TACI contained in the different TACI‐Fc constructs
plasmid number encoding these proteins (see Table 1). aa, amino acid resid
transmembrane domain. (b) UV elution profile of a size exclusion chromato
kDa) or with protein A or protein G‐purified TACI‐Fc or BCMA‐Fc construc
underlined in red. (c) SDS‐PAGE (10% or 12% acrylamide) and Coomassie b
panel (b). Input: Protein after Protein A or G affinity purification. MW stan
refer to standards (Std) shown on the left of each gel, knowing that red pr
indicated with red asterisks, and presumptive Fc fragments with black aster
fractions, revealed with anti‐human or anti‐TACI antibodies. (d) HEK293 c
presence or absence of heparin. Results are expressed as the ratio of mea
presence of heparin. In the presence of heparin, all samples gave backgroun
BCMA, B cell maturation antigen; TACI, transmembrane activator and calc3.2 | Purified, dimeric forms of TACI‐Fc do not
interact with cell surface proteoglycans
The extracellular domain of TACI comprises 165 amino acids and con-
tains two cysteine‐rich domains (CRD1 at position 33–67 and CRD2 at
position 70–104) that mediate interactions with BAFF and APRIL.
Atacicept, which contains amino acid residues 30–110 of TACI (TACI
(30–110)‐Fc), does not bind to HEK293 cells (Figure 1), yet TACI is( (
cans. (a) Schematic representation of human TACI. Portions of the
are shown with thick vertical red lines. Numbers at the top refer to
ues; CRD, cysteine‐rich domain; ID, intracellular domain; TMD,
graphy column loaded with a mixture of standards of indicated MW (in
ts, as indicated. Fractions chosen for further analysis are indicated and
lue analysis of 10‐μg protein per lane of size‐fractionated proteins from
dards indicated on the left are valid for the first gel. For the next ones,
oteins correspond to 72 and 28 kDa, respectively. Target proteins are
isks. The insert shows a western blot analysis of 50 ng of the indicated
ells were stained with the indicated proteins at 10 μg·ml−1, in the
n fluorescence intensity (MFI) in the absence of heparin to that in the
d MFI. The experiment was performed three times with similar results.
ium‐modulator and cyclophilin ligand (CAML)‐interactor
8 KOWALCZYK‐QUINTAS ET AL.BJPreported to bind to proteoglycans (Bischof et al., 2006; Moreaux et al.,
2009). In an attempt to map the proteoglycan binding site of TACI,
TACI‐Fc proteins containing various portions of extracellular TACI
were studied (Figure 2a). Proteins obtained by affinity purification on
Protein A or G were subsequently resolved by size exclusion chroma-
tography. These preparations often contained high MW material that
eluted in the void of the column (fraction 8 + 9) and a protein smaller
in size that eluted in the inclusion volume of the column at sizes(a)
(b)
(c)
FIGURE 3 Atacicept does not interfere with heparin activity. (a) Heparin
Xa) in the presence of human plasma (containing endogenous anti‐thrombin
in the presence of the indicated proteins (each at 100 μg·ml−1), or of poly‐l
representative experiment out of three similar ones with identical results i
were incubated overnight in the presence of a lethal (5 ng·ml−1) dose of Fc‐
the presence of the indicated amounts of heparin. Cell viability was measur
out of three is shown. (c) Heparin was incubated overnight at 37°C in med
inhibit binding of Fc‐APRIL to HEK293 cells was monitored. The X‐axis dis
was performed three times. (d) Same as panel (b), but using BCMA:Fas rep
duplicates. The experiment was performed three times. (e) Same as panel (d
performed three times with identical results. (f) BCMA:Fas reporter cells we
heparin. The experiment was performed three times with identical results.
the TNF family; BAFFR, BAFF receptor; BCMA, B cell maturation antigencompatible with TACI‐Fc dimers (Figure 2b). In some instances, the
included peak was split into a larger peak containing the TACI‐Fc
fusion protein and a smaller peak containing a presumptive protease
cleavage fragment with the Fc portion only (Figure 2b,c). In most
cases, TACI‐Fc after purification on Protein A or G contained a set
of contaminants migrating as a smear by SDS‐PAGE and that were
mainly recovered in the void volume of the size exclusion column
(Figure 2c). Several TACI‐Fc constructs post purification on Protein A(d)
(e)
(f)
activity was measured as its ability to inhibit activated factor X (factor
). The dose‐dependent inhibition of factor Xa by heparin was measured
ysine (poly‐K; at 90 μg·ml−1). Mean ± SEM of duplicate measures. One
s shown. (b) Reporter cells expressing the BAFFR:Fas fusion receptor
BAFF, in the presence of increasing concentrations of atacicept, and in
ed with a colorimetric test. Mean ± SEM of duplicates. One experiment
ium, or with reporter cells in medium, after which time its ability to
plays fluorescence on a log scale (3 × 102 to 5 × 104). The experiment
orter cells and a lethal (20 ng·ml−1) dose of Fc‐BAFF. Mean ± SEM of
), but with a lethal (20 ng·ml−1) dose of Fc‐APRIL. The experiment was
re cultured overnight with titrated amounts of Fc‐APRIL, plus or minus
APRIL, a proliferation‐inducing ligand; BAFF, B cell activating factor of
KOWALCZYK‐QUINTAS ET AL. 9BJPor G bound weakly, compared to the positive control Fc‐APRIL, but
specifically to HEK293 cells (Figure 2d). The high MW fractions, which
contain some of the target proteins but also contaminants, often
showed some binding to HEK293 cells, but purified, dimeric TACI‐Fc,
including atacicept, did not bind to cell surface proteoglycans, regard-
less of the portion of TACI attached to the Fc (Figure 2d). Thus, we
confirmed that atacicept does not bind to HEK293 cells and further
extended this observation to several other dimeric TACI‐Fc constructs,
including those containing the entire extracellular domain of TACI.
3.3 | Atacicept and an atacicept‐APRIL complex do
not interfere with the function of low MW heparin
When increasing concentrations of heparin were added to human
plasma samples supplemented with both activated bovine factor X
(factor Xa) and a chromogenic substrate for factor Xa, a dose‐depen-
dent inhibition of factor Xa was observed that reflects inhibition of
the protease in a ternary complex of anti‐thrombin (present in plasma),
heparin, and factor Xa (Figure 3a). Not surprisingly, the action of poly‐
anionic heparin was inhibited by poly‐cationic poly‐lysine (Figure 3a)
but heparin activity was insensitive to the presence of atacicept
(Figure 3a). Moreover, heparin activity was insensitive to the presence
of a proteoglycan binding‐competent form of Fc‐hAPRIL plus or minus
atacicept, and to (non‐size‐fractionated) TACI (2–159)‐Fc that, unlike
atacicept, showed some binding to cell surface proteoglycans
(Figure 2c,d). We conclude from these experiments that none of the
APRIL or TACI‐containing reagents tested interfere with heparin activ-
ity, whether or not they bind to proteoglycans. In particular, atacicept,
alone or in complex with APRIL, did not interfere with heparin activity
in this assay.
3.4 | Heparin does not interfere with the ability of
atacicept to inhibit BAFF and APRIL
Atacicept does not bind to proteoglycans and does not inhibit heparin
activity (Figures 1, 2, and 3a). Therefore, binding and inhibition of
BAFF by atacicept is predicted to be insensitive to the presence of
heparin. BAFF activity can be conveniently monitored using reporter
cell‐based assays in which a Jurkat T cell line stably expressing fusion
proteins containing the extracellular domains of BAFFR or BCMA,
fused to the transmembrane and intracellular domains of the death
receptor Fas, undergo Fas‐mediated death in response to BAFF (for
BAFFR:Fas and BCMA:Fas reporter cells) or APRIL (for BCMA:Fas
reporter cells; Schuepbach‐Mallepell et al., 2015). When reporter cells
were exposed to a fixed, lethal dose of Fc‐BAFF, all cells died, unless
increasing concentrations of atacicept were present to prevent death.
The presence of up to 32 IU·ml−1 of heparin did not affect inhibition of
Fc‐BAFF by atacicept (Figure 3b,d). It is noteworthy that heparin
remained active after an overnight incubation on reporter cells, as
measured by its ability to inhibit the binding of Fc‐APRIL to HEK293
cells (Figure 3c). In contrast to the inhibition of Fc‐BAFF, the inhibition
of Fc‐APRIL was about twofold more efficient in the presence of hep-
arin (Figure 3e), a result that can be readily explained by the twofolddecrease of Fc‐APRIL activity on reporter cells in the presence of hep-
arin (Figure 3f). Taken together, these results indicate that the activity
of atacicept in blocking Fc‐BAFF and Fc‐APRIL is not altered in the
presence of heparin but that the activity of Fc‐APRIL is slightly
reduced in the presence of heparin.
3.5 | Multimers of atacicept bind to cell surface
proteoglycans
Although TACI‐Fc was previously shown to bind to proteoglycans
(Bischof et al., 2006; Moreaux et al., 2009), our results with various
dimeric TACI‐Fc constructs show no such interactions, suggesting that
TACI‐Fc may require multimerization and/or aggregation to stably
bind to proteoglycans. We found that incubation of atacicept with cys-
teine resulted in efficient formation of high MW, disulfide‐linked
atacicept species, as judged by SDS‐PAGE analysis of fractions under
reducing and non‐reducing condition (Figure 4a,b), which were indeed
potent at binding cell‐surface proteoglycans in HEK293 cells (Figure 4
c). In addition to proteoglycans, high MW atacicept species were also
able to bind BAFF at the cell surface, but less efficiently than dimeric
TACI‐Fc (Figure 4c). Twenty BAFF 3‐mer can assemble as a capsid‐like
particle called BAFF 60‐mer, which does not dissociate upon atacicept
binding (Vigolo et al., 2018). BAFF 60‐mer–atacicept complexes also
bound cell‐surface proteoglycans in HEK293 cells, implying that oligo-
merization rather than disulfide‐bond formation is relevant for
multimeric atacicept to bind to PG (Figure 4d). As cysteine did not
induce multimerization of TACI‐CRD1‐Fc or Fc only, we used the
BAFF 60‐mer‐mediated multimerization assay to attempt and map
the proteoglycan‐binding site(s) of TACI. Control proteins (TNFR2‐Fc,
EDAR‐Fc, or Fc alone) did not bind to HEK293 cells, even in the pres-
ence of BAFF 60‐mer. In contrast, in the presence of BAFF 60‐mer, all
fusion proteins with a BAFF binding site (atacicept, TACI‐Fc constructs
with CRD1, CRD2 or both, BCMA and BAFFR) bound HEK293 cells in
a heparin‐inhibitable manner (Figure 4e). This suggests that weak pro-
teoglycan‐binding units located in TACI CRD1, TACI CRD2, BCMA,
BAFFR, and/or the Fc portion are reinforced upon oligomerization.
3.6 | Atacicept in the human circulation does not
bind to proteoglycans
After a single subcutaneous administration of 150‐mg atacicept in a
healthy subject, atacicept in the circulation could be detected through
its binding to BAFF‐expressing cells, but not to control cells, for up to
2 weeks after administration. Heparin did not affect staining, indicat-
ing that atacicept does not form multimers under these conditions,
or that if they form, they are not retained into the serum fraction
(Figure 5a,b).
3.7 | Atacicept multimers and atacicept in the human
circulation do not interfere with heparin activity
Two independent preparations of high MW atacicept obtained by





FIGURE 4 Multimers of atacicept bind to proteoglycans. (a) Size exclusion chromatography elution profile of atacicept incubated for 48 hr at 37°
C in phosphate buffer without cysteine. Online monitoring of absorbance at 280 nm is shown as a line. Fractions analysed by SDS‐PAGE and
Coomassie blue staining (20 μl) under non‐reducing (top gel) or reducing conditions (bottom gel) are shown in the background. Sizes of MW
standards for SDS‐PAGE are shown on the right, and those for the size exclusion chromatography are shown on the top. The vertical dotted line
marks the elution position of dimeric atacicept. (b) Same as panel (a), except that 20‐mM cysteine was included in the 48 hr incubation. The
experiment was performed five times (but the Coomassie under non‐reducing conditions was performed twice). (c) HEK293 cells, with or without
expression of membrane‐bound BAFF, were stained by FACS with atacicept (dimers) or atacicept multimers (from fraction 10, see panel (b)) at the
indicated concentrations, in the presence or absence of heparin. MFI, mean fluorescence intensity. The experiment was performed three times.
Points are monoplicates. (d) HEK 293 cells were incubated with the indicated concentrations of atacicept and BAFF 60‐mer, in the presence or
absence of heparin, and stained by FACS anti‐hFc. The experiment was performed three times. (e) HEK293 cells were incubated with various Fc‐
containing proteins (or no Fc‐containing protein: Ø) at 5 μg·ml−1 and with BAFF 60‐mer at 2 μg·ml−1 and then analysed by FACS anti‐hIgG. The
ratio of the mean fluorescence intensity (MFI) of staining performed in triplicate without or with heparin are shown. Mean ± SEM. The experiment
was performed three times with similar results. Ten micrograms of the Fc‐containing proteins (6 μg for mBAFFR‐Fc) used in these experiments
were analysed by SDS‐PAGE and Coomassie blue staining under reducing conditions. BAFF, B cell activating factor of the TNF family; BAFFR,
BAFF receptor
10 KOWALCZYK‐QUINTAS ET AL.BJPinhibition assay (Figure 5c,d) despite marked binding to proteoglycans
(Figure 4c). Sera of healthy subjects before or 24 hr after administra-
tion of 150‐mg atacicept (Figure 5e,f) and sera of patients before or
after weekly treatments with high dose (150 mg) atacicept during
24 weeks had no inhibitory effect on clinically relevant amounts of
heparin (Figure 5g,h). These results indicate that atacicept, even after
prolonged contact with plasma or after forced multimerization, cannot
interfere with heparin activity.3.8 | No evidence of atacicept interaction with
proteoglycans in vivo
HEK293 cells are only partly representative of the cellular diversity
present in a living organism, and it was therefore still possible that
atacicept, or putative atacicept multimers that would be formed
post‐administration, would interact with proteoglycans in vivo. Thus,






FIGURE 5 Atacicept in serum and atacicept multimers do not interfere with heparin activity. (a) HEK293 cells were stained by FACS, in the
presence or absence of heparin, with atacicept contained in sera samples collected at the indicated time points from a healthy subject who
received 150 mg atacicept. D, day; PK, pharmacokinetics. The experiment was performed twice with sera of subject 219, and once with sera of
subject 221, treated identically, with similar results. (b) Same as panel (a), except that HEK293‐hBAFF cells were stained. (c) Heparin activity assay
(inhibition of activated factor X) performed in the presence of PBS, 90 μg·ml−1 of poly‐lysine (Poly‐K), or 100 μg·ml−1 of dimeric atacicept. (d) Same
as panel (c), but with two independent preparations of atacicept multimers at 100 μg·ml−1. (e, f) Same as panel (c), but with sera from healthy
subjects, before or 24 hr after administration of 150 mg of atacicept. (g, h) Same as panels (e) and (f), but with sera of patients before or after
24 weeks of treatment with weekly administration of 150‐mg atacicept. Experiments in panels (c)–(h) were performed twice with similar results.
Mean ± SEM of duplicates (SEM is smaller than symbol size). BAFF, B cell activating factor of the TNF family
KOWALCZYK‐QUINTAS ET AL. 11BJP14 days. At these time points, plasma was collected before or 20 min
after intravenous administration of a high dose (1,000 IU·kg−1) of hep-
arin. Heparin activity in plasma of treated mice was high in all cases (6–
22 IU·ml−1, on average 15 IU·ml−1), indicating successful administration
(Figure 6a). Several lines of evidence indicate that heparin should have
been able to detach proteoglycan‐bound molecules in the vasculature:
First, in 293T cells, an incubation as short as 5 min with 0.1 IU·ml−1 of
heparin was sufficient to fully detach pre‐bound Flag‐APRIL (Figure 6
b). Second, heparin in plasma post‐treatment was sufficient to com-
pete with Flag‐APRIL binding to 293T cells (Figure 6c). Third, heparin
treatment significantly increased triglyceride lipase activity in plasma,
suggesting that it had mobilized endogenous proteoglycan‐bound lipo-
protein lipase (Figure 6d). Levels of active atacicept were determined
in plasma, before and after heparin administration, using a reporter cell
assay that can measure active atacicept across a wide range of con-
centrations (Figure 6e). No change in active atacicept was detected
before versus after heparin administration (Figure 6f). This, however,
did not exclude that heparin could have released a ligand‐boundversion of atacicept. This ligand‐occupied atacicept would not be
detected in the active atacicept assay. Thus, AlphaLisa was used to
measure total levels of atacicept. As this assay detects ligand‐bound
atacicept less efficiently than unbound atacicept (Figure 6g), the assay
was also performed after an acid dissociation step that overcomes
ligand‐induced quenching of the detection signal (Figure 6h). In the
absence of acid dissociation, average atacicept levels peaked at
9 μg·ml−1 at Day 1 and then decreased to 1.5, 0.6, and 0.3 μg·ml−1
after Days 3, 7, and 14. After acid dissociation, average measured
values for atacicept were 8, 1.6, 1.2, and 0.9 μg·ml−1 at Days 1, 3, 7,
and 14, respectively (Figure 6i). Significantly higher atacicept levels
detected after acid dissociation indicate the accumulation of ligand‐
bound atacicept at late time points (Figure 6i), a conclusion reinforced
by the measure of BAFF in plasma that increased to high levels at Days
7 and 14, despite the fact that BAFF detection was attenuated by the
presence of atacicept in this experimental readout (Figure 6j,k). No dif-
ferences were observed for levels of active or total atacicept before
versus after high dose heparin administration, arguing against the
(a) (b) (c) (d)




FIGURE 6 No evidence that atacicept binds to proteoglycans in vivo. Wild‐type mice were treated subcutaneously without (n = 5) or with
atacicept at 5 mg·kg−1; 24 hr (D1, n = 6) or 72 hr (D3, n = 6) later, plasma was collected, and then 1 IU·g−1 of heparin was administered
intravenously, and 20 min later, plasma was collected again. (a) Heparin activity in plasma was measured with the activated factor X (factor Xa)
inhibition assay. *P<.05, significantly different as indicated; one‐way ANOVA with Bonferroni's multiple comparison test. (b) 293T cells stained
with a complex of atacicept bound to Flag‐APRIL were exposed for the indicated times to the indicated concentrations of heparin, after which time
cells were washed and bound atacicept was detected. The experiment was performed three times. (c) The activity of heparin in plasma was
measured as its ability to prevent binding of Flag‐APRIL to 293T cells. In this assay, cells were incubated with Flag‐APRIL first, and plasma was
added afterwards. X‐axis shows fluorescence on a log scale (102–2 × 105). The experiment was performed three times. (d) Triglyceride lipase
activity was measured in plasma of mice (n = 13) before or after heparin administration, using a quenched fluorescent triglyceride (TG) derivative as
substrate. The assay was performed twice in the presence of an excess of heparin. *P<.05, significantly different as indicated; paired t‐test. (e) A
standard curve of active atacicept was measured by its ability to protect BAFFR:Fas reporter cells from Fc‐BAFF‐induced death. The experiment
was performed three times. (f) Active atacicept was measured in mouse plasma before (n = 5), or 1 day (n = 5), 3 days (n = 5), or 7 days (n = 1) after
atacicept administration. Active atacicept concentrations were derived from the EC50 of Fc‐BAFF inhibition. Values obtained in plasma of heparin‐
treated mice were corrected by the blood dilution factor caused by heparin administration. The dotted line shows the lower limit of quantification.
Measures were performed in duplicate. The experiment was done three times with identical results. (g) A standard curve of atacicept diluted in
mouse plasma was measured by AlphaLISA, in the presence or absence of 200 ng·L−1 of recombinant mouse BAFF, using a matched pair of anti‐
TACI antibodies. (h) Same as panel (g), except that samples were submitted to an acid dissociation procedure to separate BAFF from atacicept.
Experiments of panels (g) and (h) were performed five times. (i) Mice received atacicept (or not, n = 6) subcutaneously at Day 0. Plasma was taken
at Days 1 (n = 6), 3 (n = 5, because not enough plasma was left from the sixth mouse), 7 (n = 6), or 14 (n = 10), before (circles) and after (triangles)
intravenous administration of heparin. Atacicept was measured by AlphaLisa in plasma samples without (white symbols) or with (black symbols) an
acid dissociation step. Values of heparin‐treated mice were corrected by the dilution factor induced by heparin administration. Measures were
performed four times on the same set of samples, with similar results. *P<.05, significantly different as indicated; one‐way ANOVA was performed
three times for conditions at Days 3, 7, and 14, respectively, with Bonferroni's multiple comparison tests at Days 7 and 14. Statistical analysis was
performed on log‐transformed data; because under these conditions, there were no significant variance inhomogeneity. (j) A standard curve of
mouse BAFF diluted in serum of a Baff−/− mouse was measured by AlphaLISA, in the presence of 0, 100, or 2000 ng·ml−1 of atacicept, using a
matched pair of anti‐mBAFF antibodies. The experiment was performed three times. (k) Circulating BAFF levels in plasma of WT mice treated
subcutaneously at Day 0 with a single dose of atacicept. Plasma was collected at Day 0 (before atacicept administration), Day 1, Day 3, Day 7, or
Day 14 after atacicept administration, and before or after administration of heparin on the day of plasma collection. BAFF levels were calculated
using the standard curve of BAFF in the absence of atacicept and are expressed as “unbound mBAFF equivalent.” Samples were measured three
times independently, with similar results. APRIL, a proliferation‐inducing ligand; BAFF, B cell activating factor of the TNF family; BAFFR, BAFF
receptor; TACI, transmembrane activator and calcium‐modulator and cyclophilin ligand (CAML)‐interactor
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KOWALCZYK‐QUINTAS ET AL. 13BJPhypothesis that a significant pool of proteoglycan‐bound atacicept,
free or ligand‐bound, exists in the vasculature (Figure 6f,i).4 | DISCUSSION
The structure of heparin, a repeated disaccharide unit of variably sul-
fated iduronic acid (mainly 2‐O‐sulfated) and N‐acetyl glucosamine
(mainly 6‐O‐ and N‐sulfated), is very similar to that of glycosamino-
glycan side chains of heparan sulfate proteoglycans and proteins that
bind these glycosaminoglycans side chains also bind to heparin (Xu &
Esko, 2014). As the BAFF and APRIL receptor TACI interacts with
syndecan‐2 and other proteoglycans (Bischof et al., 2006), it was
necessary to address the question of a potential drug interaction of
heparin and atacicept, which contains a part of the extracellular
domain of TACI. No binding of atacicept to cell surface proteogly-
cans was detected. An attempt to map the proteoglycan‐binding site
on TACI first yielded intriguing results: Purified dimeric TACI‐Fc did
not bind detectably to proteoglycans, whatever the TACI sequence
contained in these constructs. Weak but specific binding was only
seen with some TACI‐Fc preparations that had not been size‐
fractionated, or with high MW fractions that usually also contained
various contaminating proteins. However, after treatment with cyste-
ine, two or more atacicept dimers were cross‐linked via disulfide
bridges. These atacicept oligomers displayed robust binding to pro-
teoglycans, suggesting that binding to proteoglycans is an intrinsic,
avidity‐dependent TACI property, and not the result of an indirect
binding via contaminants. Oligomerization of atacicept through bind-
ing to BAFF 60‐mer also increased binding to proteoglycans. With
this later assay, all TACI constructs containing either CRD1 and/or
CRD2 interacted with proteoglycans, as well as the few BCMA and
BAFFR constructs that were tested, suggesting that weak proteogly-
can binding might be a general property of BAFF‐binding CRDs,
and/or of the Fc portion, and not of a putative distinct cluster of
positively‐charged amino acid residues. Our results showing that
atacicept and other dimeric TACI‐Fc constructs do not bind to proteo-
glycans do not rule out that TACI may physiologically interact with
proteoglycans, possibly after self‐ or ligand‐induced multimerization.
Discrepant or inconsistent results obtained across studies for binding
of TACI‐Fc to proteoglycans could simply reflect varying amounts of
aggregates in TACI‐Fc preparations that had not always been size‐
fractionated.
As dimeric atacicept does not bind to proteoglycans, it was
expected not to interfere with the activity of heparin, and it did not.
Atacicept in complex with APRIL did not affect heparin activity up to
an atacicept concentration of 100 μg·ml−1, which is at least 10‐fold
higher than could be achieved with atacicept in vivo. Even artificially
multimerized atacicept, which binds to proteoglycans, did not change
heparin activity. The lack of interference of high MW atacicept or
atacicept–APRIL complexes with heparin activity can be explained by
the observation that the affinity of heparin for different proteins can
differ by up to three or four orders of magnitude (Xu & Esko, 2014).
The affinity of APRIL for proteoglycans in BCMA‐ and TACI‐negativecell lines was measured in the range of 20–80 μM (Dillon, Gross,
Ansell, & Novak, 2006), whereas the affinity of heparin for anti‐throm-
bin is 3–20 nM, that is, 1000‐fold stronger (Bjork et al., 1992; Xu &
Esko, 2014).
Heparin binds APRIL and might indirectly alter its binding to
atacicept. The binding site of TACI to APRIL has been characterized
in detail in a co‐crystal structure (Hymowitz et al., 2005), showing that
the interaction takes place on a face of APRIL that is opposite to the
basic stretch known to facilitate heparin binding (Hendriks et al.,
2005; Ingold et al., 2005). This does not support the hypothesis that
heparin could interfere with the APRIL–TACI interaction, and our
results indeed showed no interference of heparin on the ability of
atacicept to inhibit BAFF or APRIL, even at heparin concentrations
higher than those achieved in clinical practice. Doses of heparin used
in the clinic vary with the desired anti‐coagulant action. For example,
after a heart attack or a thrombosis, doses of up to 10 000 IU hep-
arin can be given intravenously (Unknown, 2011), which would result
in plasma concentrations of about 2 IU·ml−1. Heparin up to concen-
trations of 32 IU·ml−1 did not affect atacicept, but decreased activity
of recombinant Fc‐APRIL about twofold in a reporter cell assay. We
speculate that the docking of Fc‐APRIL on cell surface proteoglycans
increases its local concentration and agonistic activity on reporter
cells and that this effect is reduced in the presence of heparin that
prevents binding of Fc‐APRIL to the surface of the reporter cells.
Heparin was shown previously to inhibit the growth factor activity
of APRIL on multiple myeloma cells by preventing its binding to pro-
teoglycans (Moreaux et al., 2009). We have further observed that
TACI (and possibly BCMA) stimulation requires ligand oligomerization
(Bossen et al., 2008). In line with this result, APRIL activity on pri-
mary B cells is enhanced by proteoglycans or heparan sulfate proteo-
glycans that would cross‐link and position the TACI/BCMA binding
domain of APRIL, making it a better activator of receptors (Kimberley
et al., 2009). Thus, although heparin is unlikely to interact with
atacicept, it might interfere with the biology of APRIL–proteoglycan
interactions, with a potential modulation of plasma cell biology in a
physiological setting. It will be interesting in the future to study
the effects of heparin on the biology of endogenous APRIL, although
this might be complicated by the vast array of proteins whose inter-
actions with proteoglycans will also be modulated by heparin (Xu &
Esko, 2014).
In conclusion, our results provide no indication that atacicept inter-
feres with heparin and vice versa, providing no reason to expect
atacicept–heparin drug interactions.ACKNOWLEDGEMENTS
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Y scale: cell counts
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FACS plots for Fig. 2D
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FACS plots for Fig. 4C
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FACS plots for Fig. 4E
Binding of Receptor-Fc – BAFF 60mer complexes
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FACS plots for Fig. 5AB
Y scale: cell counts
X scale: FL2 (log from 
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FACS plots for Fig. 6B
Y scale: cell counts






























































































Binding of Flag-ACRP-APRIL A88-1088 / atacicept
complex to HEK293 cells (revealed anti-Flag)
